---
$id: https://graph.org.ai/products/commodity/51112001
$type: Product
source: UNSPSC
code: "51112001"
title: "Capecitabine"
class: "51112000"
classTitle: "Tyrosine kinase inhibitors"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Capecitabine

**UNSPSC Code**: 51112001
**Class**: [Tyrosine kinase inhibitors](Tyrosine kinase inhibitors.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a pyrimidine antagonist with the molecular formula C15H22FN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6804DJ8Z9U, chemically known as pentyl 1-(5-deoxy-beta-d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate but generally known as capecitabine, which bears US NIH Compound Identifier 60953. European Medicines Agency schedules Capecitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12474MIG. The term CAPECITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules capecitabine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule capecitabine under HS 29349990 and SITC 51579. As of Q4 2014, CAPECITABINE remains the US FDA Preferred Term for this commodity. Capecitabine bears US NLM identifiers UMLS ID C0671970 and NCI Concept Code C1794. SMILES: FC1CN(C2OC(C(O)C2O)C)C(=O)NC1NC(=O)OCCCCC.

